May 21st 2025
The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.
Roche Pulls Out of Agreement With Repare Therapeutics to Develop Novel Cancer Therapy
February 13th 2024Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.